However, it may be seen used off-label for cUTI/cIAI at this higher dosage (ID provider discretion) if the pt is not clinically stable. 2/2 https://t.co/gQ2zcPNpTt @BWDionne @jeffpears0n @davidwkubiak @AmabelK326 @GReardonPharma

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy https://t.co/oBgogqyqp7 #ScientiaVH

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy. https://t.co/xiauTYO3vr #AMR #esbl

REVIEW: Ceftolozane/tazobactam for the treatment of complicated intra-abdomina | IDR @DovePress https://t.co/Sk6SLrWx4H

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy. https://t.co/3Si5GObV2z #hvhebron #malinf @DovePress [Text complet]

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy. https://t.co/ZPHlDVlL9u

Ceftolozane/tazobactam for the treatment of complicated intra-abdomina | IDR - Dove Medical Press https://t.co/RPUOq6tpTg #AMR #esbl